PharmAust and Elanco Execute Data Sharing Agreement for Dog Cancer Trials

- PharmAust and Elanco commence data sharing agreement.
- PharmAust gains ability to expedite Phase II clinical trial program in dogs with cancer.

29 January 2019 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, is pleased to announce it has executed a Data and Regulatory Rights Agreement with Elanco US Inc to assist in the development of monepantel as an anticancer therapeutic in dogs.

Under this agreement, Elanco will permit PharmAust to reference certain Elanco controlled safety and blood chemistry data that were generated for the regulatory approval of monepantel in Australia, New Zealand and 27 countries within the European Union, as an anti-parasitic drug in livestock animals. Given that livestock animals are destined for human consumption, data and documentation generated for this purpose are required to be extremely comprehensive, adhering to a very high level of precision and detail.

This Data and Regulatory Rights Agreement supports the Option Agreement executed between Elanco and PharmAust on 12 April 2018, providing PharmAust with the ability to more efficiently develop its Phase II clinical trials in dogs.

PharmAust Chief Scientific Officer, Dr Richard Mollard stated, “PharmAust is grateful for Elanco’s continued support in testing the effects of monepantel in dogs with cancer. Having access to this documentation and data package enables PharmAust to approach regulatory authorities in the US and Europe to potentially expedite the early proof of principle Phase II clinical trials in pet owner’s dogs with cancer.”

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):
PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated ~Aus$3.02m in revenues in the 2018 FY.